Profile Response Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com


Molecular Profile CDKN2A loss
Therapy Palbociclib
Indication/Tumor Type ovarian cancer
Response Type sensitive

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
CDKN2A loss ovarian cancer sensitive Palbociclib Phase II Actionable In a Phase II trial (TAPUR), treatment with Ibrance (palbociclib) resulted in a disease control rate of 38% (10/27, 3 partial responses, 7 stable disease greater than 16 weeks), objective response rate of 11% (3/27), median progression-free survival of 8 weeks, and median overall survival of 33 weeks in patients with ovarian cancer harboring a CDKN2A alteration including loss (n=21), mutation (n=5), or both (n=2) (PMID: 42456088; NCT02693535). 42456088
PubMed Id Reference Title Details
(42456088) Palbociclib in Patients With Ovarian Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study. Full reference...